Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation

Stem Cells Translational Medicine

Volumn 3, Issue 7, 2014, Pages 849-856

  Lacerda, Lara ^a   Reddy, Jay P ^a   Liu, Diane ^a   Larson, Richard ^a   Li, Li ^a   Masuda, Hiroko ^a   Brewer, Takae ^a   Debeb, Bisrat G ^a   Xu, Wei ^a   Hortobágyi, Gabriel N ^a   Buchholz, Thomas A ^a   Ueno, Naoto T ^a   Woodward, Wendy A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Inflammatory breast cancer; Local recurrence; Radiation; Statins

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; SIMVASTATIN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER CELL LINE; CANCER CONTROL; CANCER RADIOTHERAPY; CLONOGENIC ASSAY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BREAST CANCER; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MASTECTOMY; OBESITY; POSTMENOPAUSE; RADIATION DOSE; RADIOSENSITIZATION; RETROSPECTIVE STUDY; TRIPLE NEGATIVE BREAST CANCER;

INFLAMMATORY BREAST CANCER; LOCAL RECURRENCE; RADIATION; STATINS;

ADULT; AGED; CELL DIFFERENTIATION; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFLAMMATORY BREAST NEOPLASMS; KAPLAN-MEIER ESTIMATE; MASTECTOMY; MCF-7 CELLS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS; PROPORTIONAL HAZARDS MODELS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK FACTORS; SIMVASTATIN; SPHEROIDS, CELLULAR; TIME FACTORS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; YOUNG ADULT;

EID: 84903521248     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2013-0204     Document Type: Article

References (45)

1. Dawood S, Merajver SD, Viens P et al. International expert panel on inflammatory breast cancer: Consensus statement for standardized diagnosis and treatment. Ann Oncol 2011; 22: 515-523.
2. Charafe-Jauffret E, Ginestier C, Iovino F et al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res 2010; 16: 45-55.
3. Rosenthal DT, Zhang J, Bao L et al. RhoC impacts the metastatic potential and abundance of breast cancer stem cells. PLoS One 2012; 7: e40979.
4. Xiao Y, Ye Y, Yearsley K et al. The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype. Am J Pathol 2008; 173: 561-574.
5. Clarke M, Collins R, Darby S et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 366: 2087-2106.
6. Meyers MO, Klauber-Demore N, OllilaDW et al. Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. Ann Surg Oncol 2011; 18: 2851-2857.
7. Panoff JE, Hurley J, Takita C et al. Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation. Breast Cancer Res Treat 2011; 128: 899-906.
8. Chen MS, Woodward WA, Behbod F et al. Wnt/beta-catenin mediates radiation resistance of Sca1+ progenitors in an immortalized mammary gland cell line. J Cell Sci 2007; 120: 468-477.
9. Phillips TM, McBrideWH, Pajonk F. The response of CD24(-/low)/CD44+ breast cancerinitiating cells to radiation. J Natl Cancer Inst 2006; 98: 1777-1785.
10. WoodwardWA, Chen MS, Behbod F et al. WNT/beta-catenin mediates radiation resistance of mousemammaryprogenitor cells. Proc Natl Acad Sci USA 2007; 104: 618-623.
11. Creighton CJ, Li X, LandisMet al. Residual breast cancers after conventional therapy display mesenchymal aswell as tumor-initiating features. Proc Natl Acad Sci USA 2009; 106: 13820-13825.
12. Li X, Lewis MT, Huang J et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008; 100: 672-679.
13. Dontu G, Abdallah WM, Foley JM et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003; 17: 1253-1270.
14. Woodward WA, Bristow RG. Radiosensitivity of cancer-initiating cells and normal stem cells (or what the Heisenberg uncertainly principle has to do with biology). Semin Radiat Oncol 2009; 19: 87-95.
15. Debeb BG, Xu W, Mok H et al. Differential radiosensitizing effect of valproic acid in differentiation versus self-renewal promoting culture conditions. Int J Radiat Oncol Biol Phys 2010; 76: 889-895.
16. Graaf MR, Beiderbeck AB, Egberts AC et al. The risk of cancer in users of statins. J Clin Oncol 2004; 22: 2388-2394.
17. Blais L, Desgagné A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: A nested case-control study. Arch InternMed 2000; 160: 2363-2368.
18. Cauley JA, Zmuda JM, Lui LY et al. Lipidlowering drug use and breast cancer in older women: A prospective study. J Womens Health (Larchmt) 2003; 12: 749-756.
19. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2012; 367: 1792-1802.
20. Ahern TP, Pedersen L, TarpMet al. Statin prescriptions and breast cancer recurrence risk: A Danish nationwide prospective cohort study. J Natl Cancer Inst 2011; 103: 1461-1468.
21. Denoyelle C, Vasse M, Körner M et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: An in vitro study. Carcinogenesis 2001; 22: 1139-1148.
22. Luan Z, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1,-2,-3, and-9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 2003; 23: 769-775.
23. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109(suppl 1): III39-III43.
24. Hakamada-Taguchi R, Uehara Y, Kuribayashi K et al. Inhibition of hydroxymethylglutarylcoenzyme a reductase reduces Th1 development and promotes Th2 development. Circ Res 2003; 93: 948-956.
25. Feleszko W, Bałkowiec EZ, Sieberth E et al. Lovastatin and tumor necrosis factoralpha exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis. Int J Cancer 1999; 81: 560-567.
26. Alber HF, Dulak J, Frick M et al. Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease. J Am Coll Cardiol 2002; 39: 1951-1955.
27. Hata Y, Miura M, Asato R et al. Antiangiogenic mechanisms of simvastatin in retinal endothelial cells. Graefes Arch Clin Exp Ophthalmol 2010; 248: 667-673.
28. Schulz MM, Reisen F, Zgraggen S et al. Phenotype-based high-content chemical library screening identifies statins as inhibitors of in vivo lymphangiogenesis. Proc Natl Acad Sci USA 2012; 109: E2665-E2674.
29. Kodach LL, Jacobs RJ, Voorneveld PW et al. Statins augment the chemosensitivity of colorectal cancer cells inducing epigenetic reprogramming and reducing colorectal cancer cell 'stemness' via the bone morphogenetic protein pathway. Gut 2011; 60: 1544-1553.
30. Mandal CC, Ghosh-Choudhury N, Yoneda T et al. Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44. J Biol Chem 2011; 286: 11314-11327.
31. Ginestier C, Monville F, Wicinski J et al. Mevalonate metabolism regulates basal breast cancer stem cells and is a potential therapeutic target. STEM CELLS 2012; 30: 1327-1337.
32. Kao J, Salari K, BocanegraMet al. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One 2009; 4: e6146.
33. Klopp AH, Lacerda L, Gupta A et al. Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells. PLoS One 2010; 5: e12180.
34. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008; 10: R25.
35. Gupta PB, Onder TT, Jiang G et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009; 138: 645-659.
36. Brewer TM, MasudaH, LiuDDet al. Statin use in primary inflammatory breast cancer: A cohort study. Br J Cancer 2013; 109: 318-324.
37. Li J, Gonzalez-Angulo AM, Allen PK et al. Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. The Oncologist 2011; 16: 1675-1683.
38. Gopalan A, Yu W, Sanders BG et al. Eliminatingdrug resistantbreast cancer stem-likecells with combination of simvastatin and gammatocotrienol. Cancer Lett 2013; 328: 285-296.
39. Menter DG, Ramsauer VP, Harirforoosh S et al. Differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sites. PLoS One 2011; 6: e28813.
40. Zhao Z, Cao X, Pan Y et al. Simvastatin downregulates HER2 via upregulation of PEA3 to induce cell death in HER2-positive breast cancer cells. Oncol Res 2012; 20: 187-195.
41. Kumar AS, Benz CC, Shim V et al. Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol Biomarkers Prev 2008; 17: 1028-1033.
42. Park YH, Jung HH, AhnJS et al. Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway. Biochem Biophys Res Commun 2013; 439: 275-279.
43. Martin BJ, van Golen KL. A comparison of cholesterol uptake and storage in inflammatory and noninflammatory breast cancer cells. Int J Breast Cancer 2012; 412581.
44. Van der Auwera I, Van Laere SJ, Van den Eynden GG et al. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res 2004; 10: 7965-7971.
45. Arias-PulidoH, Chaher N, GongY et al. Tumor stromal vascular endothelial growth factor A is predictive of poor outcome in inflammatory breast cancer. BMC Cancer 2012; 12: 298.